Home / Business and Economy / Wockhardt's New Antibiotics Fight Superbugs
Wockhardt's New Antibiotics Fight Superbugs
1 Dec
Summary
- Wockhardt is developing novel antibiotics for resistant infections.
- New treatments target sepsis and pneumonia with unique mechanisms.
- The company also offers insulin analogs and recombinant vaccines.
Wockhardt Limited, a global pharmaceutical and biotech firm, is at the forefront of developing novel antibiotics to combat the escalating threat of drug-resistant bacteria. The company's pipeline includes ZAYNICH, a dual-action antibiotic targeting sepsis and pneumonia, and FOVISCU for resistant gram-negative infections.
Further innovation includes MIQNAF for azithromycin-resistant pathogens and ODRATE, a daily combination therapy for outpatient parenteral antimicrobial therapy. These advancements aim to provide critical solutions for challenging infections and address the growing global health crisis.
In addition to its antibiotic research, Wockhardt is also advancing treatments in other key areas. The company develops insulin analogs, glucagon-like peptide-1 agonists, and offers recombinant vaccines like Biovac-B, alongside treatments for anemia such as Wepox and various insulin formulations. Delivery devices for insulin further complement their patient care offerings.
